CD40LG and neoplasm: Constituting an inactive anti-IgM antibody-drug conjugate which is actuated in the proteolytic tumor environment, the molecule unites an enhanced safety profile due to tumor-proximity restricted activation and potent anti-tumor efficacy relying on a highly cytotoxic payload.